Edgewise Therapeutics, Inc. EWTX
39.34
(1.82)
(4.42%)
as of 25 Sep
- Market cap
- $4.4B
- P/E
- 0.0×
Follow EWTX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
26.51 | 19.85 | 22.61 | 16.24 |
Net Debt/EBITDA |
11.65 | 9.32 | 9.16 | 7.41 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.86 | 0.77 | 0.87 | 0.74 | |
Capex/Depreciation |
0.06 | 0.08 | 0.61 | 0.15 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.33) | (0.38) | (0.40) | (0.39) | |
Cash per Share |
5.34 | 5.15 | 4.66 | 4.28 | |
Shareholders Equity per Share |
5.30 | 5.07 | 4.60 | 4.16 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.30 | 5.07 | 4.60 | 4.16 | |
Free Cash Flow |
(34.86) | (38.66) | (42.80) | (42.50) | |
Working Capital |
552.25 | 516.02 | 487.25 | 442.48 | |
Capital Expenditures |
(0.09) | (0.07) | (0.26) | (0.03) | |
Net Current Asset Value |
549.08 | 513.04 | 484.47 | 439.91 | |
| Other line items | |||||
Quick Ratio |
26.03 | 19.37 | 22.16 | 15.86 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.33) | (0.37) | (0.40) | (0.39) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
5.90 | 5.79 | 8.04 | 6.49 | |
Average Assets |
547.37 | 519.71 | 486.46 | 546.51 | |
Average Common Equity |
523.76 | 490.74 | 461.46 | 518.57 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates